Skip to main content

Table 4 Patient information for predominant histological subtypes in pathological stage II + IIIA

From: The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010

  Total Group B
(Lepidic)
Group C
(Papillary + acinar
 + variant)
Group D
(Solid + micropapillary)
p-value
n 697 57 503 137  
Sex (male/female), n (%) 426/271 (61.1%) 34/23 (58.8%) 305/198 (60.8%) 87/50 (63.5%) 0.905
Age, mean ± SD 66.57 ± 9.53 68.00 ± 8.35 66.71 ± 9.69 65.41 ± 9.45 0.223
Smoking history ( ±), n (%) 424/248 (63.2%) 34/23 (58.8%) 291/194 (60.6%) 99/31 (76.2%) 0.003
Operation time (min.), mean ± SD 217.89 ± 72.68 219.02 ± 76.10 219.27 ± 72.75 213.19 ± 71.95 0.711
Invasion, n (%)
   Lymphatic vessel invasion ( ±) 406/219 (65.0%) 24 /29 (45.2%) 293/155 (65.4%) 89/35 (71.8%)  < 0.001
   Vascular invasion ( ±) 345/282 (55.1%) 13/40 (26.5%) 246/206 (54.4%) 86/38 (70.5%)  < 0.001
   Pleural invasion ( ±) 324/396 (45.0%) 12/45 (23.5%) 226/275 (45.1%) 70/65 (51.9%)  < 0.001
 EGFR mutation ( ±) 182/284 (39.5%) 16/22 (44.1%) 142/197 (41.9%) 24/65 (27.0%) 0.048
 Adjuvant therapy ( ±) 453/233 (66.0%) 36/19 (63.3%) 319/177 (64.3%) 98/37 (72.6%) 0.249
 Pathological stage II / IIIA 375/322 (53.8%) 25/32 (43.9%) 270/233 (53.7%) 73/64 (53.3%) 0.960
  1. AIS Adenocarcinoma in situ, MIA Minimally invasive adenocarcinoma, SD Standard deviation